HNN3.0
Register
Register
Register

Project cooperationUpdated on 23 January 2026

Opportunities for Collaboration

Consultant at SIL Pharma Pty Ltd

Brisbane, Australia

About

SIL Pharma partners with organisations that want quality and compliance to genuinely support their work. We bring over 25 years of hands-on experience across pharmaceuticals, clinical research, and medical devices, working closely with teams to strengthen quality systems, support clinical development, and navigate regulatory expectations with confidence.

Our expertise covers supplier quality audits, QA compliance, clinical trial support, technical writing, and validation and technology transfer activities. From GMP and GCP audits and CAPA support, to HREC submissions, trial documentation, and manufacturing validation, we focus on practical, risk-based solutions that work in real operational settings. We help teams improve processes, prepare for audits and inspections, and build sustainable systems that stand up over time.

We are looking to collaborate with pharmaceutical, biotech, and medical device companies, ingredient suppliers, CROs, CMOs, and growing SMEs who value a hands-on, collaborative approach. Ideal partners are those seeking a trusted quality and regulatory partner — whether to support ongoing operations, scale up manufacturing, prepare for inspections, or deliver high-quality clinical and technical documentation. We’re particularly well suited to long-term partnerships where expertise, transparency, and shared ownership of outcomes matter.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Similar opportunities

  • Project cooperation

    ECRIN: Pan‑European Infrastructure Partner for Multinational Clinical Trials in Horizon Europe Health 2026–2027

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Maria Alexandra Rujano

    Project Manager at European Clinical Research Infrastructure Network (ECRIN)

    Paris, France

  • Project cooperation

    Regulatory science & patient-centered digital platforms with applied AI

    • Partner seeks Consortium/Coordinator
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

    Innokenty Puntikov

    Tender Manager at First Line Software

    Miami, United States

  • Project cooperation

    Clinical Affairs & Research Support for Medical Devices (with Hospital & In-House Laboratory)

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Alejandro Torres

    Head of Business Development and Marketing at D.med Software

    Málaga, Spain